• Trendlyne logo
  • Markets
  • Alerts
  • F&O
  • MF
  • Reports
  • Screeners
  • Subscribe
  • Superstars
  • Portfolio
  • Watchlist
  • Insider Trades
  • Results
  • Data Downloader
  • Events Calendar
  • What's New
  • Explore
  • FAQs
  • Widgets
More
    Search stocks
    IND USA
    IND
    IND
    IND
    USA
    • Stocks
    • Futures & Options
    • Mutual Funds
    • News
    • Fundamentals
    • Reports
    • Corporate Actions
    • Alerts
    • Shareholding
    logo
    Laurus Labs Ltd.
    26 Apr 2025
    864.40
    -0.87%
    Laurus Labs Eyes 24% EBITDA Margin In FY26 After Strong Q4 Results
    Laurus Labs Eyes 24% EBITDA Margin In FY26 After Strong Q4 Results
    NDTV Profit
    Laurus Labs clocked an EBITDA margin of 27.7% in Q4 FY25 as against 18% in the year-ago period.
    Copy LinkShare onShare on Share on Share on
    Laurus Labs Ltd. is trading below its 30 day SMA of 882.5
    logo
    Lupin Ltd.
    25 Apr 2025
    1973.60
    -0.39%
    Lupin-led price cut slashes cost of key TB drug pretomanid by 25%
    Business Line
    Multiple drug price reductions bring BPaLM treatment regimen price down 47 percent, at $310, since December 2022.
    Copy LinkShare onShare on Share on Share on
    Number of FII/FPI investors increased from 979 to 987 in Jun 2025 qtr.
    logo
    Laurus Labs Ltd.
    25 Apr 2025
    864.40
    -0.87%
    Laurus Labs falls 6% despite strong Q4 results: Here's what brokerages say
    Business Standard
    Laurus Labs stock was quoting at 618.50, down 4.18 per cent from the previous session's closing price of 645.50
    Copy LinkShare onShare on Share on Share on
    Laurus Labs Ltd. is trading above its 200 day SMA of 684.7
    Laurus Labs Q4 profit rises 3-fold to 234 cr; revenue at 1,440 cr
    Business Line | 24 Apr 2025 2 more
    Laurus Labs Q4 results: Net profit rises three-fold to Rs 234 crore
    Business Standard | 24 Apr 2025
    Laurus Labs Q4 Results: Profit Rises 200% To Rs 234 Crore, Beats Estimates
    NDTV Profit | 24 Apr 2025
    logo
    Morepen Laboratories Ltd.
    24 Apr 2025
    49.23
    0.86%
    Morepen stock soars over 14% on growth plans
    Business Line
    Morepen Laboratories said its 325-crore formulation business was targeting 1,000 crore in five years, on the back of local and global sales
    Copy LinkShare onShare on Share on Share on
    Number of FII/FPI investors decreased from 57 to 49 in Jun 2025 qtr
    logo
    Akums Drugs & Pharmaceuticals Ltd.
    24 Apr 2025
    446.20
    -1.12%
    Akums Drugs signs MoA with TNAU to boost R&D in agri-based pharma formulations
    Business Line
    The collaboration will also offer industrial training and internships, fostering hands-on learning for students in formulation and processing.
    Copy LinkShare onShare on Share on Share on
    Akums Drugs & Pharmaceuticals Ltd. is trading below all available SMAs
    logo
    Syngene International Ltd.
    24 Apr 2025
    635.50
    0.62%
    Syngene International's shares slide 13% amid cautious FY26 outlook
    Business Line
    The company flagged near-term pressures on margins, citing a fluid macroeconomic environment and the integration of recent investments
    Copy LinkShare onShare on Share on Share on
    Syngene Internationa.. has an average target of 1030.00 from 1 broker.
    Syngene International Shares Decline As Q4 Earnings Miss Estimates
    NDTV Profit | 24 Apr 2025 4 more
    Syngene International tumbles 10% as Q4 profit slips; key highlights here
    Business Standard | 24 Apr 2025
    Syngene posts 3% drop in Q4 PAT; revenue crosses 1,000 cr for first time
    Business Line | 23 Apr 2025
    Syngene Q4 results: PAT down 3%, revenue from ops up 11% to 1,018 cr
    Business Standard | 23 Apr 2025
    Syngene International Q4 Results: Profit Misses Estimates
    NDTV Profit | 23 Apr 2025
    logo
    Lupin Ltd.
    24 Apr 2025
    1973.60
    -0.39%
    Lupin gets USFDA nod for generic kidney disease treatment drug Tolvaptan
    Business Standard
    Pharma major Lupin Ltd on Thursday said it has received approval from the US health regulator for its generic version of Tolvaptan tablets indicated for a certain type of kidney disease. The approval by the US Food and Drug Administration (USFDA) is for the abbreviated new drug application for Tolvaptan tablets of strengths 15 mg, 30 mg, 45 mg, 60 mg, and 90 mg, Lupin said in a regulatory filing. These are bioequivalent to Jynarque tablets in the same strengths of Otsuka Pharmaceutical Company Ltd, it added. "Lupin is the exclusive first-to-file for this product and is eligible for 180 days of generic drug exclusivity. This product will be manufactured at Lupin's Nagpur facility and will be launched soon," the company said. Commenting on the approval, Lupin CEO Vinita Gupta said,"This marks a significant entry into the nephrology segment and demonstrates our commitment to addressing the unmet needs of patients globally." Tolvaptan is indicated to slow kidney function decline in .
    Copy LinkShare onShare on Share on Share on
    Lupin Ltd. is trading above its 100 day SMA of 1960.5
    Lupin gets USFDA nod for generic kidney disease treatment drug
    Business Line | 24 Apr 2025
    logo
    Sanofi Consumer Healthcare India Ltd.
    24 Apr 2025
    4797.60
    1.03%
    Investors rush to buy Sanofi India shares ahead of ex-dividend date; detail
    Business Standard
    The ex-dividend date marks the day a stock begins trading without the right to receive the declared dividend, meaning investors must own the stock before this date to be eligible
    Copy LinkShare onShare on Share on Share on
    Number of FII/FPI investors decreased from 136 to 114 in Jun 2025 qtr
    Last chance: Sanofi India, Muthoot Finance to go ex-dividend on April 25
    Business Standard | 24 Apr 2025
    logo
    Alkem Laboratories Ltd.
    24 Apr 2025
    5442.00
    -0.32%
    Stock to buy today: Alkem Laboratories (5,232) BUY
    Business Line
    Alkem Laboratories share price can rise to 5,600-5,700
    Copy LinkShare onShare on Share on Share on
    Number of FII/FPI investors increased from 535 to 551 in Jun 2025 qtr.
    logo
    Sai Life Science Ltd.
    23 Apr 2025
    882.60
    -0.51%
    DHL Express, Sai Life Sciences team up for GoGreen Plus partnership
    Business Line
    Copy LinkShare onShare on Share on Share on
    Sai Life Science Ltd. has gained 60.77% in the last 1 Year
    more
    loading
    Trendlyne Logo Trendlyne
    Stay ahead of the market
    Markets Today
    • Nifty 50 today
    • Sensex today
    • Latest Quarterly results
    • FII & DII data today
    Dashboard
    • Industry & Sector analysis
    • ETFs
    • Mutual Funds
    • Bullish & Bearish spread
    • Global Indices
    Tools
    • Compare stocks
    • Widgets
    • Data Downloader
    • Excel Connect
    IPOs
    • Dashboard (Mainboard & SME)
    • Upcoming IPOs
    • Recently Listed IPOs
    • Most Successful IPOs
    Upcoming IPOs
    • DSM Fresh Foods
    • Greenleaf Envirotech
    • NSB BPO Solutions
    Quick Links
    • Contact us
    • Blogs
    • FAQs
    Company
    • Privacy
    • Terms of Use
    • Disclaimer
    Trendlyne Products
    • Starfolio
    • SmartOptions
    • Trendlyne US Global
    Get Mobile App
    • Android
    • iOS

    Copyright © 2025 Giskard Datatech Pvt Ltd (RA SEBI Reg No: INH000022507)